Ligand Pharmaceuticals IncorporatedLGNDNASDAQ

Revenue (LTM)

$268M

+60.4% YoY

Net Income (LTM)

$124M

+3186.6% YoY

Free Cash Flow

$49M

Revenue CAGR (5Y)

+2.6%

Marginsimproving

FCF$0.0B

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	242	196↓18.8%	131↓33.1%	167↑27.3%	268↑60.4%
Gross Profit	179	143↓20.0%	96↓32.9%	156↑62.1%	261↑67.6%
Operating Income	104	3↓97.1%	12↑293.2%	-23↓289.3%	47↑308.8%
Net Income	57	-33↓158.4%	52↑256.3%	-4↓107.7%	124↑3186.6%
EBITDA	143	81↓43.1%	101↑24.2%	41↓59.5%	193↑372.5%
EPS Diluted	3.34	-1.98↓159.3%	2.94↑248.5%	-0.22↓107.5%	6.13↑2886.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	20	45↑130.5%	23↓49.0%	72↑215.0%	175↑141.9%
Total Current Assets	465	264↓43.3%	237↓9.9%	332↑39.6%	832↑151.0%
Total Assets	1,298	763↓41.2%	787↑3.2%	942↑19.6%	1,561↑65.7%
Total Current Liabilities	42	99↑137.2%	17↓83.0%	37↑121.1%	37↑0.9%
Total Liabilities	476	165↓65.3%	86↓47.8%	111↑29.0%	543↑388.1%
Total Equity	821	597↓27.2%	701↑17.3%	830↑18.5%	1,017↑22.5%
Total Debt	324	88↓73.0%	6↓93.0%	7↑15.2%	451↑6254.6%
Net Debt	305	43↓86.0%	-17↓139.3%	-65↓288.4%	277↑524.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	79	138↑74.9%	50↓64.0%	97↑95.8%	49↓49.1%
Capital Expenditure	-9	-18↓104.6%	-54↓200.4%	-20↑63.5%	-0↑97.7%
Free Cash Flow	70	120↑71.2%	-4↓103.6%	77↑1912.0%	49↓36.8%
Stock-Based Comp	39	60↑55.4%	26↓57.3%	41↑59.6%	0
Net Change in Cash	-28	25↑189.6%	-22↓186.5%	49↑323.8%	103↑107.9%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance